{"id":"NCT01607112","sponsor":"GlaxoSmithKline","briefTitle":"A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above","officialTitle":"A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-10","primaryCompletion":"2012-07-31","completion":"2012-07-31","firstPosted":"2012-05-28","resultsPosted":"2013-12-06","lastUpdate":"2018-09-07"},"enrollment":119,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Fluarix/Influsplit SSW 2012-2013","otherNames":[]}],"arms":[{"label":"Fluarix/Influsplit 18-60 Years Group","type":"EXPERIMENTAL"},{"label":"Fluarix/Influsplit > 60 Years Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' trivalent influenza vaccine manufactured for the 2012/2013 influenza season administered in adults (18 to 60 years) and in elderly (over 60 years).","primaryOutcome":{"measure":"Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains","timeFrame":"At Day 0 and Day 21","effectByArm":[{"arm":"Fluarix/Influsplit 18-60 Years Group","deltaMin":20.57,"sd":null},{"arm":"Fluarix/Influsplit > 60 Years Group","deltaMin":19.02,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":4,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Pain","Fatigue","Headache","Myalgia","Sweating increase"]}}